Localized Therapy in Early- and Intermediate-Stage HCC

Opinion
Video

Medical oncologists outline localized therapy options for patients with early- and intermediate-stage hepatocellular carcinoma.

Recent Videos
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
A panel of 5 experts on liver cancer
A panel of 5 experts on liver cancer
A panel of 5 experts on liver cancer
A panel of 5 experts on liver cancer
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Related Content
Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment?

Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment?

Natasha Bahri, MD, MS;Christiana Crook, MS;Daneng Li, MD
November 12th 2024
Article

Given that well-differentiated grade 3 NETs are relatively new, standard-of-care treatment options are undefined.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

PDUFA Dates Pushed for Sotorasib/Obeticholic Acid in GI Indications

PDUFA Dates Pushed for Sotorasib/Obeticholic Acid in GI Indications

Ariana Pelosci
October 22nd 2024
Article

The FDA has pushed back PDUFA dates for sotorasib and obeticholic acid for metastatic CRC and primary biliary cholangitis indications.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

Adrienne Bruce Shannon, MD;Sean Dineen, MD;Muhammad Talha Waheed, MD
April 15th 2024
Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Ten votes were cast against PD-L1 as an efficacy biomarker for therapies intended to treat patients with gastric or GEJ adenocarcinoma.

ODAC Votes Against PD-L1 as Efficacy Biomarker in Gastric Cancers

Russ Conroy
September 26th 2024
Article

Ten votes were cast against PD-L1 as an efficacy biomarker for therapies intended to treat patients with gastric or GEJ adenocarcinoma.

Data from a real-world study further illustrates clinical benefit in patients with cholangiocarcinoma receiving pemigatinib.

Real-world Data Supports Findings from FIGHT-202 in Cholangiocarcinoma

Harrison Widelitz
September 26th 2024
Article

Data from a real-world study further illustrates clinical benefit in patients with cholangiocarcinoma receiving pemigatinib.